Vital Therapies (VTL) Upgraded to Sell at ValuEngine

ValuEngine upgraded shares of Vital Therapies (NASDAQ:VTL) from a strong sell rating to a sell rating in a report published on Wednesday.

A number of other research firms also recently issued reports on VTL. Zacks Investment Research downgraded Vital Therapies from a hold rating to a sell rating in a research report on Saturday, March 17th. Raymond James Financial reissued a buy rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Finally, BidaskClub raised Vital Therapies from a sell rating to a hold rating in a research report on Wednesday, January 31st.

How to Become a New Pot Stock Millionaire

VTL stock opened at $6.80 on Wednesday. Vital Therapies has a 12-month low of $2.25 and a 12-month high of $7.30. The stock has a market cap of $288.11, a price-to-earnings ratio of -5.19 and a beta of 4.63.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings results on Tuesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). During the same quarter in the previous year, the firm earned ($0.37) earnings per share. equities research analysts forecast that Vital Therapies will post -1.35 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of VTL. Dimensional Fund Advisors LP purchased a new stake in shares of Vital Therapies in the third quarter worth about $116,000. Bank of Montreal Can purchased a new stake in shares of Vital Therapies in the fourth quarter worth about $118,000. JPMorgan Chase & Co. boosted its position in shares of Vital Therapies by 1,985.3% in the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after buying an additional 24,241 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Vital Therapies in the fourth quarter worth about $179,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Vital Therapies in the fourth quarter worth about $197,000. 25.99% of the stock is owned by institutional investors.

WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/2018/04/01/vital-therapies-vtl-upgraded-to-sell-at-valuengine.html.

Vital Therapies Company Profile

Vital Therapies, Inc, a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply